Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab
Scott V. Bratman, S.Y. Cindy Yang, Marco Iafolla, Zhihui Liu, Aaron R. Hansen, Philippe L. Bédard, Stéphanie Lheureux, Anna Spreafico, Albiruni Abdul Razak, Svetlana Shchegrova, Maggie C. Louie, Paul R. Billings, Bernhard Zimmermann, Himanshu Sethi, Alexey Aleshin, Dax Torti, Kayla Marsh, Jenna Eagles, Iulia Cirlan, Youstina Hanna, Derek Clouthier, Scott Lien, Pamela S. Ohashi, Wei Xu, Lillian L. Siu, Trevor J. Pugh
Topics & Concepts
PembrolizumabMedicineOncologyInternal medicineBiomarkerCirculating tumor DNAClinical trialResponse Evaluation Criteria in Solid TumorsImmunotherapyImmune checkpointCancerPhases of clinical researchBiologyBiochemistryCancer Genomics and DiagnosticsCancer Immunotherapy and BiomarkersLung Cancer Treatments and Mutations